4D Molecular Therapeutics (FDMT) Return on Equity: 2021-2025
Historic Return on Equity for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to -0.53%.
- 4D Molecular Therapeutics' Return on Equity fell 28.00% to -0.53% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.53%, marking a year-over-year decrease of 28.00%. This contributed to the annual value of -0.39% for FY2024, which is 2.00% down from last year.
- According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Return on Equity is -0.53%, which was down 20.24% from -0.44% recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Return on Equity ranged from a high of -0.18% in Q2 2024 and a low of -0.53% during Q3 2025.
- Its 3-year average for Return on Equity is -0.35%, with a median of -0.32% in 2023.
- Per our database at Business Quant, 4D Molecular Therapeutics' Return on Equity increased by 26bps in 2024 and then declined by 28bps in 2025.
- Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Return on Equity stood at -0.26% in 2021, then dropped by 18bps to -0.45% in 2022, then rose by 13bps to -0.32% in 2023, then increased by 1bps to -0.30% in 2024, then fell by 28bps to -0.53% in 2025.
- Its Return on Equity stands at -0.53% for Q3 2025, versus -0.44% for Q2 2025 and -0.36% for Q1 2025.